{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:38:05Z","timestamp":1771846685529,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":801,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41379-020-0561-9","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T08:06:45Z","timestamp":1589357205000},"page":"2198-2207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Jean-Christophe","family":"Tille","sequence":"first","affiliation":[]},{"given":"Andr\u00e9 F.","family":"Vieira","sequence":"additional","affiliation":[]},{"given":"Caroline","family":"Saint-Martin","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5007-2964","authenticated-orcid":false,"given":"Lounes","family":"Djerroudi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-6307","authenticated-orcid":false,"given":"La\u00ebtitia","family":"Furhmann","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-8949","authenticated-orcid":false,"given":"Francois-Clement","family":"Bidard","sequence":"additional","affiliation":[]},{"given":"Youlia","family":"Kirova","sequence":"additional","affiliation":[]},{"given":"Anne","family":"Tardivon","sequence":"additional","affiliation":[]},{"given":"Fabien","family":"Reyal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6793-3273","authenticated-orcid":false,"given":"Matthieu","family":"Carton","sequence":"additional","affiliation":[]},{"given":"Anne","family":"Vincent-Salomon","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1038\/s41379-020-0561-9_bib1","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.ejca.2010.05.013","article-title":"Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma","volume":"46","author":"Gruel","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-020-0561-9_bib2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.steroids.2012.11.002","article-title":"Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems","volume":"78","author":"Sikora","year":"2013","journal-title":"Steroids"},{"key":"10.1038\/s41379-020-0561-9_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.critrevonc.2014.07.003","article-title":"Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?","volume":"92","author":"Guiu","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1038\/s41379-020-0561-9_bib4","unstructured":"World Health Organization Classification of Tumours Editorial Board. Breast tumours. 5th ed. Vol. 2. Lyon: International Agency for Research on Cancer; 2019."},{"key":"10.1038\/s41379-020-0561-9_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.2005.03.111","article-title":"Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes","volume":"23","author":"Cristofanilli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/annonc\/mdl114","article-title":"Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution","volume":"17","author":"Tubiana-Hulin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjc.6604229","article-title":"High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies","volume":"98","author":"Bollet","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1038\/s41379-020-0561-9_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejca.2003.08.015","article-title":"The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile","volume":"40","author":"Mathieu","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-020-0561-9_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2275-4","article-title":"Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma","volume":"16","author":"Adachi","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1038\/s41379-020-0561-9_bib10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.breast.2013.06.001","article-title":"The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients","volume":"22","author":"Korhonen","year":"2013","journal-title":"Breast"},{"key":"10.1038\/s41379-020-0561-9_bib11","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/JCO.2007.14.9336","article-title":"Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials","volume":"26","author":"Pestalozzi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejca.2003.08.007","article-title":"Wide metastatic spreading in infiltrating lobular carcinoma of the breast","volume":"40","author":"Ferlicot","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-020-0561-9_bib13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1038\/s41379-020-0561-9_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/srep18517","article-title":"Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer","volume":"6","author":"Michaut","year":"2016","journal-title":"Sci Rep"},{"key":"10.1038\/s41379-020-0561-9_bib15","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1200\/JCO.2015.64.0334","article-title":"Genomic characterization of primary invasive lobular breast cancer","volume":"34","author":"Desmedt","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib16","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib17","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib18","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.breast.2017.03.010","article-title":"Tumor infiltrating lymphocytes in early breast cancer","volume":"37","author":"Pruneri","year":"2018","journal-title":"Breast"},{"key":"10.1038\/s41379-020-0561-9_bib20","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/jnci\/djx268","article-title":"Immune infiltration in invasive lobular breast cancer","volume":"110","author":"Desmedt","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/s41379-020-0561-9_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"10.1038\/s41379-020-0561-9_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib23","doi-asserted-by":"crossref","unstructured":"MacGrogan G, Mathieu MC, Poulet B, Penault-Llorca F, Vincent-Salomon A, Roger P, et al. [Pre-analytical stage for biomarkerassessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]. Ann Pathol. 2014;34:366\u201372.","DOI":"10.1016\/j.annpat.2014.08.017"},{"key":"10.1038\/s41379-020-0561-9_bib24","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib25","unstructured":"Amin MB. AJCC cancer staging manual. 8th ed. Chicago, Illinois, Springer; 2018."},{"key":"10.1038\/s41379-020-0561-9_bib26","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update.","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1038\/s41379-020-0561-9_bib27","first-page":"144","volume":"16","author":"Balaton","year":"1996","journal-title":"Ann Pathol"},{"key":"10.1038\/s41379-020-0561-9_bib28","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1365-2559.2000.01006.x","article-title":"High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases","volume":"37","author":"Zafrani","year":"2000","journal-title":"Histopathology"},{"key":"10.1038\/s41379-020-0561-9_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.clbc.2013.10.019","article-title":"Survival outcomes in breast cancer patients with low estrogen\/progesterone receptor expression","volume":"14","author":"Balduzzi","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1038\/s41379-020-0561-9_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2017.06.005","article-title":"Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis","volume":"18","author":"Chen","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1038\/s41379-020-0561-9_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1245\/s10434-012-2588-8","article-title":"Effect of ASCO\/CAP guidelines for determining ER status on molecular subtype","volume":"20","author":"Deyarmin","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2011","journal-title":"Lancet"},{"key":"10.1038\/s41379-020-0561-9_bib33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1309\/AJCP34CYSATWFDPQ","article-title":"Low ER+ breast cancer: is this a distinct group?","volume":"141","author":"Gloyeske","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-020-0561-9_bib34","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cncr.26431","article-title":"Impact of low estrogen\/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers","volume":"118","author":"Raghav","year":"2012","journal-title":"Cancer"},{"key":"10.1038\/s41379-020-0561-9_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/his.14036","article-title":"Prognostic Significance of nucleolar assessment in invasive breast cancer","volume":"76","author":"Elsharawy","year":"2020","journal-title":"Histopathology"},{"key":"10.1038\/s41379-020-0561-9_bib36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.1989.323","article-title":"Invasive lobular carcinomas of the breast\u2013the prognosis of histopathological subtypes","volume":"60","author":"du Toit","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1038\/s41379-020-0561-9_bib37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10549-012-2002-z","article-title":"Invasive lobular breast cancer: subtypes and outcome","volume":"133","author":"Iorfida","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-020-0561-9_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/85.1.1","article-title":"Alveolar variant of invasive lobular carcinoma of the breast. A tumor rich in estrogen receptors","volume":"85","author":"Shousha","year":"1986","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-020-0561-9_bib39","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdz395","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.","volume":"30","author":"Park","year":"2019","journal-title":"Ann Oncol."},{"key":"10.1038\/s41379-020-0561-9_bib40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib42","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib44","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1200\/JCO.2012.46.2440","article-title":"Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial","volume":"31","author":"Metzger-Filho","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0561-9_bib45","doi-asserted-by":"crossref","first-page":"e1133","DOI":"10.1016\/j.clbc.2018.04.006","article-title":"HER2-positive lobular versus ductal carcinoma of the breast: pattern of first recurrence and molecular insights","volume":"18","author":"Da Ros","year":"2018","journal-title":"Clin Breast Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-0561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-0561-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222004422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222004422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-0561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:36:01Z","timestamp":1760229361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222004422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0893395222004422"],"URL":"https:\/\/doi.org\/10.1038\/s41379-020-0561-9","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-020-0561-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}